חוב לטווח קצר של החברה: SeaStar Medical Holding Corporation (ICU)

The development of SCD systems for kidneys and FDA support are driving the expansion of SeaStar Medical (ICU), which, combined with regular sales of blood purification consumables, creates a sustainable cash flow. The current liability ratio visualizes this financial burden, where the value 0.00 captures this metric. Further growth is based on an increasing number of clinics treating multi-organ failure.

For SeaStar Medical Holding (ICU), which faces high capital burn and FDA regulatory risks, analyzing short-term accounts payable allows for real-time liquidity monitoring. This metric measures the volume of obligations maturing within one year, helping investors identify the debt trend's pivot point and assess the business's ability to service its debts while awaiting clinical trial results.